Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic synergy between decitabine and platinum derivatives

11 Sept 2015

Abstract excerpt

BACKGROUND: Aberrant epigenetic silencing of tumor suppressor genes has been recognized as a driving force in cancer. Epigenetic drugs such as the DNA methylation inhibitor decitabine reactivate genes and are effective in myeloid leukemia, but resistance often develops and efficacy in solid tumors is limited. To improve their clinical efficacy, we searched among approved anti-cancer drugs for an epigenetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Research and Treatments
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26366234
DOI: 10.1186/s13148-015-0131-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic synergy between decitabine and platinum derivativesPMID 26366234Read ↗

DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical applicationSemantic proximity Read ↗

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1Semantic proximity Read ↗

DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of artSemantic proximity Read ↗

DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer CellsSemantic proximity Read ↗

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer CellsSemantic proximity Read ↗

Chromatin Remodeling Is Required for Gene Reactivation after Decitabine-Mediated DNA HypomethylationSemantic proximity Read ↗

Synergistic Effect of Epigenetic Modulator Decitabine and Metformin in the Battle Against Gastric Cancer: A Potential Therapeutic StrategySemantic proximity Read ↗

Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumorsSemantic proximity Read ↗

Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer.Semantic proximity Read ↗

CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma linesSemantic proximity Read ↗

Epigenetic treatment combinations to effectively target cisplatin‐resistant germ cell tumors: past, present, and future considerationsSemantic proximity Read ↗

CDK4/6 inhibitors enhance oxaliplatin efficacy in colorectal cancer with RB-dependent and tumor-selective activity in intestinal modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.